IUB288 是一种稳定长效的胰高血糖素修饰肽,同时也是高选择性的胰高血糖素受体 (Glucagon Receptor) 激活剂,可刺激 cAMP 生成,提升血浆及肝脏中 FGF21 的表达水平,调控胆汁酸代谢,并抑制肝脏 HMGCR 的表达,从而改善高胆固醇血症,增强胰岛素敏感性,提升核心体温,增加能量消耗,抑制食物摄入,还可诱发高血糖及葡萄糖耐受不良,因此可用于饮食诱导型肥胖、2 型糖尿病及肥胖相关葡萄糖耐受不良的研究。
IUB288
产品编号: MS-J85698 分子式: C177H272N42O53S 分子量: 3868.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IUB288 是一种稳定长效的胰高血糖素修饰肽,同时也是高选择性的胰高血糖素受体 (Glucagon Receptor) 激活剂,可刺激 cAMP 生成,提升血浆及肝脏中 FGF21 的表达水平,调控胆汁酸代谢,并抑制肝脏 HMGCR 的表达,从而改善高胆固醇血症,增强胰岛素敏感性,提升核心体温,增加能量消耗,抑制食物摄入,还可诱发高血糖及葡萄糖耐受不良,因此可用于饮食诱导型肥胖、2 型糖尿病及肥胖相关葡萄糖耐受不良的研究。

生物实验数据

生物活性 IUB288 is a stable, long-acting glucagon-modified peptide and a highly selective glucagon receptor activator that stimulates cAMP production, elevates FGF21 expression levels in plasma and liver, regulates bile acid metabolism, and inhibits hepatic HMGCR expression, thereby ameliorating hypercholesterolemia, enhancing insulin sensitivity, elevating core body temperature, increasing energy expenditure, and suppressing food intake, while also inducing hyperglycemia and glucose intolerance, and can therefore be used for research on diet-induced obesity, type 2 diabetes, and obesity-related glucose intolerance.
IC50 & Target

FGF21

 

GLP-1

 

体外研究
(In Vitro)

IUB288 (0.0001-10 nM; 5 h) 可在 HEK293 细胞中强效激活胰高血糖素受体,且活性优于天然胰高血糖素。
IUB288 (0.0001-10 nM; 5 h) 可激活 HEK293 细胞中的胰高血糖素样肽-1 (GLP-1) 受体,其效力比对胰高血糖素受体的效力低约 100 倍,显示出极高的 GcgR 选择性。
IUB288 (0.133 nmol/mL; 120 min) 可显著上调大鼠 H4IIE 肝癌细胞中 FGF21 的基因表达。

Real Time qPCR

Cell Line: rat H4IIE hepatoma cells
Concentration: 0.133 nmol/mL
Incubation Time: 120 min
Result: Significantly increased relative FGF21 mRNA expression in H4IIE cells compared to control.
体内研究
(In Vivo)

IUB288 (0.3-10 nmol/kg/day;每日给药;最长 18 天) 可在饮食诱导肥胖的雄性 C57Bl/6J 小鼠中强效降低体重和脂肪量、降低血浆胆固醇水平、升高血糖并抑制肝脏 HMGCR 的表达。
IUB288 (10 nmol/kg;腹腔注射;单次给药) 增加普通饲料喂养小鼠的血糖水平,并刺激肥胖小鼠短暂分泌 FGF21;而 IUB288 (10 nmol/kg/天;每日给药;连续 16 天) 的 长时间处理可增加普通饲料喂养小鼠的食物摄入量与血浆甘油三酯水平,但不会改变其体重。
IUB288 (10 nmol/kg/天;每日给药;连续 7 天) 可降低瘦素受体缺陷型 db/db 小鼠的体重、提升核心体温并增强其胰岛素敏感性,且不会改变血糖水平或食物摄入量。
IUB288 (10 nmol/kg/天;每日给药;持续 20 天) 可预防野生型 (WT) 小鼠的饮食诱导型体重增加,提高能量消耗 (EE) 并降低血浆胆固醇水平,但这些效应在 FGF21 缺陷型小鼠中完全消失,表明 FGF21 是 IUB288 发挥大多数长期代谢作用所必需的。
IUB288 (10 nmol/kg/天;每日给药;共 18 天) 可显著增加饮食诱导肥胖小鼠的肝脏 FGF21 表达水平和循环 FGF21 含量。
IUB288 (10 nmol/kg;皮下注射;每日) 可降低饮食诱导肥胖 C57Bl/6J 小鼠的体重并抑制其摄食;同时,联合使用胆汁酸螯合树脂可逆转该小鼠伴随的葡萄糖不耐受症状,且还能增强 IUB288 的抗肥胖作用。

Animal Model: C57Bl/6J (male, 11 months old, diet-induced obesity via 9-month high-fat diet)
Dosage: 0.3 nmol/kg/day; 1 nmol/kg/day; 3 nmol/kg/day; 10 nmol/kg/day
Administration: daily; up to 18 days
Result: Lowered initial body weight by nearly 30% at 10 nmol/kg/day.
Decreased cumulative food intake at 10 nmol/kg/day.
Elevated ad libitum blood glucose in a dose-dependent manner.
Diminished fat mass at 10 nmol/kg/day
Corrected hypercholesterolemia, lowering plasma cholesterol from approximately 125 mg/dL to 65 mg/dL at 10 nmol/kg/day.
Inhibited hepatic 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR) expression at 10 nmol/kg/day
Raised plasma triglycerides in chow-fed mice at 10 nmol/kg/day.
Exerted no obvious body weight reduction at doses of 0.3, 1, and 3 nmol/kg/day.
Animal Model: db/db (male, 12 weeks old, leptin receptor-deficient, type 2 diabetes)
Dosage: 10 nmol/kg/day
Administration: daily; 7 days
Result: Decreased relative body weight to around 95% of baseline weight on day 7.
Elevated core body temperature.
Produced no changes in ad libitum and fasting blood glucose.
Strengthened insulin sensitivity and accelerated glucose disappearance rate (Kd).
Exerted no obvious shifts in food intake compared with vehicle group.
Animal Model: C57Bl/6J (male, 12 weeks old, wild-type and FGF21-deficient littermates, obesity prevention via high-fat diet initiation)
Dosage: 10 nmol/kg/day
Administration: unspecified route, daily; 20 days
s.c., daily; 72 hours
Result: Lowered body weight to approximately 88% of starting weight in WT mice.
Diminished fat mass in WT mice.
Decreased lean mass in WT mice.
Elevated cumulative energy expenditure (EE) in WT mice.
Boosted locomotor activity during light phase in WT mice.
Lowered plasma cholesterol levels in WT mice.
Raised ad libitum blood glucose concentrations in WT mice.
Exerted no detectable impacts on body weight, fat mass, lean mass, EE or locomotor activity in FGF21-/- mice.
Lost the capacity to lower plasma cholesterol in FGF21-/- mice.
Triggered stronger elevations of plasma triglycerides and nonesterified free fatty acids (NEFAs) in FGF21-/- mice compared with WT mice.
Caused milder elevation of ad libitum blood glucose in FGF21-/- mice relative to WT mice.
Provoked glucose intolerance in both WT and FGF21-/- mice against corresponding vehicle groups.
Animal Model: C57Bl/6J (male, 11 months old, diet-induced obesity via 9-month high-fat diet)
Dosage: 10 nmol/kg/day
Administration: daily; 18 days
Result: Increased hepatic FGF21 mRNA expression to ~7-fold relative to vehicle.
Increased plasma FGF21 to ~400 pg/dL.
Animal Model: C57Bl/6J (diet-induced obese, high-fat diet fed)
Dosage: 10 nmol/kg
Administration: s.c.; daily
Result: Reduced body weight in diet-induced obese mice.
Suppressed food intake in diet-induced obese mice.
Caused glucose intolerance in diet-induced obese mice.
Restored glucose excursion to the levels of vehicle-treated controls when co-administered with 3% Cholestyramine supplemented high-fat diet.
Enhanced weight loss when co-administered with 3% or 1.5% Cholestyramine, or 2% or 4% Colesevelam supplemented high-fat diet.
Completely suppressed food intake when co-administered with 4% Colesevelam supplemented high-fat diet.
Reduced yet failed to fully suppress food intake when co-administered with 2% Colesevelam supplemented high-fat diet.

化学信息

分子量 3868.37
分子式 C177H272N42O53S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础